Abstract
There is no standard therapy after progression to immune checkpoint inhibitor (ICI) therapy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). Chemotherapy has been shown to increase objective response rates after ICIs. The aim of this study was to evaluate the efficacy and safety of a weekly cetuximab-paclitaxel (PC regimen) after checkpoint inhibitors in R/M SCCHN.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
